Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303199 · ClinicalTrials.gov registry record · Phase 1
Study of ZIO-101 in Multiple Myeloma
A Phase 1 study, sponsored by Alaunos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00303199 is a Phase 1 study that has completed, run by Alaunos Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT00303199, a Phase 1 study, has completed, sponsored by Alaunos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
Interventions
- DRUG ZIO-101 (Darinaparsin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303199
The ClinicalTrials.gov registry entry for NCT00303199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alaunos Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZIO-101 (Darinaparsin) is the first listed.
NCT00303199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303199 about?
NCT00303199 is a clinical study titled "Study of ZIO-101 in Multiple Myeloma". The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
What is the current status of trial NCT00303199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2006-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00303199?
The interventions under investigation include: ZIO-101 (Darinaparsin) (DRUG).
Who is sponsoring clinical trial NCT00303199?
This trial is sponsored by Alaunos Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.